Hepatitis C News and Research RSS Feed - Hepatitis C News and Research

Hepatitis C is a blood-borne virus that infects the liver, where it causes significant inflammation, damage and disruption of normal liver function. According to estimates by the World Health Organization, around 3 to 4 million people worldwide are infected with hepatitis C every year.

The hepatitis C virus is usually transmitted through contact with the blood of an infected individual and, most commonly, people catch it through sharing contaminated needles when injecting illegal drugs.

Hepatitis C infection is categorized into an acute and a chronic stage. The acute phase describes the first 6 months of infection when there are not necessarily any symptoms. Around one quarter of people manage to clear the infection during this stage before disease progresses to the chronic stage.

People who go on to develop chronic hepatitis C may develop jaundice which turns the skin and whites of the eyes yellow. This is caused by the build-up of a yellow-colored substance in the blood called bilirubin that would usually be broken down by the liver if it was healthy. Chronic infection may eventually cause fibrosis and scarring (cirrhosis) of the liver, liver cancer or end stage liver failure.

Hepatitis C can be treated with antiviral medications that that are designed to disrupt the multiplication of virus particles inside the body and prevent liver damage.
ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. [More]
‘Most’ cirrhotic HBV patients benefit from adding adefovir to lamivudine

‘Most’ cirrhotic HBV patients benefit from adding adefovir to lamivudine

Response-guided addition of adefovir to lamivudine-based therapy not only maintains long-term viral suppression in Chinese chronic hepatitis B patients with compensated liver cirrhosis, research suggests, but also improves liver function. [More]
Mylan to distribute Sovaldi and Harvoni tablets in India for treatment of chronic hepatitis C

Mylan to distribute Sovaldi and Harvoni tablets in India for treatment of chronic hepatitis C

Mylan Inc. today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India. [More]
Betaretrovirus may infect patients with primary biliary cirrhosis

Betaretrovirus may infect patients with primary biliary cirrhosis

In a new study published in Alimentary Pharmacology & Therapeutics, researchers at the University of Alberta's Faculty of Medicine & Dentistry have shown that a betaretrovirus which resembles a mouse mammary tumor virus infects patients with the rare liver disease, primary biliary cirrhosis (PBC). [More]
Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2014, including a summary of recent corporate highlights. [More]
IL-23 predicts PegIFN response in chronic HBV

IL-23 predicts PegIFN response in chronic HBV

High baseline serum levels of interleukin-23 can help to identify hepatitis B e antigen-positive chronic hepatitis B patients who are likely to respond to pegylated interferon treatment, a Chinese study indicates. [More]
Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Long-term tenofovir disoproxil fumarate therapy is effective in Chinese patients with chronic hepatitis B virus infection who have relapsed after treatment with multiple nucleos(t)ide analogues, research suggests. [More]
TDF monotherapy ‘reasonable’ option in entecavir-resistant HBV

TDF monotherapy ‘reasonable’ option in entecavir-resistant HBV

Researchers from the Republic of Korea have found that the efficacy of tenofovir disoproxil fumarate monotherapy is comparable to that of TDF plus entecavir in chronic hepatitis B patients with genotypic resistance to entecavir. [More]
Rutgers patient gets second chance at life following liver transplant

Rutgers patient gets second chance at life following liver transplant

Mati Muñoz is 65 years old - filled with the enthusiastic energy that comes with a second chance at life. A decade ago, says Muñoz, who lives in Woodbridge Township, N.J., her liver was being destroyed by hepatitis C, a viral disease she believes she contracted as a girl in her native Cuba from a poorly sterilized needle used in a medical procedure. [More]
Report: Proposed SDGs may not achieve policy objectives without clearer, more measurable targets

Report: Proposed SDGs may not achieve policy objectives without clearer, more measurable targets

The proposed UN Sustainable Development Goals (SDGs) - a universal set of goals to guide international development to 2030 - will struggle to achieve their stated policy objectives without clearer, more measurable targets, according to a new report released today by the International Council for Science and the International Social Science Council. [More]

Door-to-door campaing encourages people to get tested for hepatitis C and to get linked to care

In Philadelphia, as in many cities, neighborhoods with high rates of hepatitis C virus (HCV) often also have limited access to screening and treatment. A new study in the Journal of General Internal Medicine shows that when expert advocates made a focused effort in a medically underserved area, they were able to help vulnerable patients leap each of the many hurdles that often keep people out of care. [More]
Despite growing shortage of donor hearts, surgeons, transplant centers reject marginal hearts

Despite growing shortage of donor hearts, surgeons, transplant centers reject marginal hearts

Surgeons and transplant centers nationwide increasingly have rejected hearts donated for transplantation despite a growing need for them, according to a new study by researchers at the Stanford University School of Medicine. [More]
AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily. [More]
GI Society releases video to spread awareness about hepatitis C

GI Society releases video to spread awareness about hepatitis C

As many as 350,000 Canadians could be suffering with hepatitis C, many of whom are unaware that they are infected, thus continuing to spread the virus. Although there is a vaccine to prevent the spread of the hepatitis A and hepatitis B viruses, there is no vaccine for hepatitis C. The good news is that with new treatments, hepatitis C is now a curable disease. [More]
BPC opens new plasma collection center in Jacksonville, North Carolina

BPC opens new plasma collection center in Jacksonville, North Carolina

Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, is pleased to announce that it has opened a new plasma collection center. The state-of-the-art, 15,000 square foot facility located at 113 Yopp Road, Jacksonville, North Carolina, is BPC's second plasma center in Jacksonville, and officially opened its doors for business on February 3, 2015. [More]
Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV"). [More]
New AGA guideline provides guidance to prevent HBV reactivation

New AGA guideline provides guidance to prevent HBV reactivation

Long-term immunosuppressive therapy can cause the hepatitis B virus (HBV) to become active, even in patients who are not aware that they are infected with the virus. A new guideline from the American Gastroenterological Association provides guidance to physicians and patients who use immunosuppressive agents for the treatment of a variety of disorders, including gastrointestinal, dermatologic, neurologic and rheumatologic, among others. [More]
HCV more common in West Africa yet lacks equal attention as HIV/AIDS or Ebola

HCV more common in West Africa yet lacks equal attention as HIV/AIDS or Ebola

More than 180 million people in the world have hepatitis C, compared with the 34 million with HIV/AIDS and the roughly 30,000 who have had Ebola. [More]
40% of prison and jail inmates have chronic medical problems, shows BJS survey

40% of prison and jail inmates have chronic medical problems, shows BJS survey

An estimated 40 percent of state and federal prisoners and jail inmates reported having a current chronic medical condition in the 2011–12 National Inmate Survey, the Bureau of Justice Statistics (BJS) announced today. [More]
Researchers develop new MRI-based technique to better detect NAFLD in children

Researchers develop new MRI-based technique to better detect NAFLD in children

Between 5 and 8 million children in the United States have nonalcoholic fatty liver disease (NAFLD), yet most cases go undiagnosed. To help address this issue, researchers at UC San Diego School of Medicine have developed a new magnetic resonance imaging (MRI)-based technique to help clinicians and researchers better detect and evaluate NAFLD in children. [More]
Advertisement
Advertisement